Page 3«..2345..1020..»

Category : Nanomedicine

Nanomedicine Market Analysis and Forecast to 2025 by Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview Murphy’s…

The global Nanomedicine Market Reports review the latest Nanomedicine market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for particular sector investments. the study reveals profitable investment strategies for Nanomedicine companies, business executives, product marketing managersand new business investors..

report evaluates the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. global Nanomedicine Market Growth has also been forecasted for the period 2020-2025, compelling into consideration the previous growth patterns, the growth drivers and the current and future trends.

Get a Sample Copy of the Report at-https://www.absolutereports.com/enquiry/request-sample/15462802

The global Nanomedicine market consists of a number of players. The company outlining of the below market players has been done in the report consisting of their business overview, financial overview and the business strategies adopted by the companies.

Nanomedicine Market Report Highlights key Market Dynamics of sector, Various definitions and classification of applications of the Nanomedicine market industry and Chain structure with Upstream Raw Materials, Sourcing Strategy and Downstream Buyers are given. Additionally, prime strategical activities in the market, which includes Nanomedicine market share, product developments, mergers and acquisitions, partnerships, etc., are discussed.

Key Companies

Market Segmentation of Nanomedicine market

Market by Application

Market by Type

Inquire Or Share Your Questions If Any Before The Purchasing This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/15462802

By Region

Key Topic Covered in Nanomedicine Market Report

Answered to the Frequently Asked Questions

WHAT IS THE SCOPE OF THE REPORT?

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

WHAT ARE THE KEY SEGMENTS IN THE MARKET?

WHICH MARKET DYNAMICS AFFECTS THE BUSINESS?

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Purchase This Report (Price 4500 USD for single user license) https://www.absolutereports.com/purchase/15462802

Detailed Table of Content of Global Nanomedicine Market 2020-2025

Table of ContentsPart 1 Market Overview1.1 Market Definition1.2 Market Development1.3 By TypeTable Type of NanomedicineFigure Global Nanomedicine Market Share by Type in 20201.4 By ApplicationTable Application of NanomedicineFigure Global Nanomedicine Market Share by Application in 20201.5 Region OverviewTable Region of NanomedicineFigure Global Nanomedicine Market Share by Region in 2020Part 2 Global Market Status and Future Forecast2.1 Global Market by RegionTable Global Nanomedicine Market by Region, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Region in 2020 (Million USD)Table Price List by Region, 2015-20192.2 Global Market by CompanyTable Global Nanomedicine Market by Company, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Company in 2020 (Million USD)Table Price List by Company, 2015-20192.3 Global Market by TypeTable Global Nanomedicine Market by Type, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Type in 2020 (Million USD)Table Price List by Type, 2015-20192.4 Global Market by ApplicationTable Global Nanomedicine Market by Application, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Application in 2020 (Million USD)Table Price List by Application, 2015-20192.5 Global Market by ForecastFigure Global Nanomedicine Market Forecast, 2020-2024 (Million USD)Part 3 Asia-Pacific Market Status and Future Forecast3.1 Asia-Pacific Market by CompanyTable Asia-Pacific Nanomedicine Market by Company, 2015-2019 (Million USD)Figure Asia-Pacific Nanomedicine Market Share by Company in 2020 (Million USD)Table Price List by Company, 2015-20193.2 Asia-Pacific Market by TypeTable Asia-Pacific Nanomedicine Market by Type, 2015-2019 (Million USD)Figure Asia-Pacific Nanomedicine Market Share by Type in 2020 (Million USD)Table Price List by Type, 2015-20193.3 Asia-Pacific Market by ApplicationTable Asia-Pacific Nanomedicine Market by Application, 2015-2019 (Million USD)Figure Asia-Pacific Nanomedicine Market Share by Application in 2020 (Million USD)Table Price List by Application, 2015-2019

.And Many more.

For Detail TOC Click Here

Contact Info:

Name: Ajay More

Email: [emailprotected]

Organization: Absolute Reports

Phone: +14242530807/+44203239 8187

Our Other report :Motion Tracker Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2026

Global Underwater Exploration Robots Market 2024: Size, Key Companies, Trends, Growth and Regional Forecasts Research

Osteotomy Plates Market 2020 Capacity Production Overview, Market Share Analysis, Demand Overview, Import Export Consumption

COVID-19 Outbreak- Global Bacterial Diagnostics in Aquaculture Market 2020 Key Players, Industry Overview, Supply Chain and Analysis to 2025

Global Permanent Magnetic Material Market Growth Factors, Product Types and Application by Regions Analysis & Forecast by 2026

Worldwide Phthalate Plasticizers Market Outlook to 2025: Emerging Trends and Will Generate New Growth Opportunities Status

Global Benazepril Market 2021: Overview, Manufacturing Cost Structure Analysis, Growth Opportunities Forecaste 2025

Global Tire Release Agents Market Outlook 2025: Top Companies, Trends and Future Prospects Details for Business Development

Global Cosmetic Nonsurgical Surgery and Procedure Market 2021: Boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2025

Global Radiation Cure Coatings Sales Market 2021: Market Growth, Trends, Revenue, Share and Demands Research Report|Coronavirus Impact

Global Recombinant Protein Vaccine Market 2020: Market Size, Share, Growth, Sales and Drivers Analysis Research Report 2024 with

Global Field-Mount Temperature Transmitters Sales Market 2026: Size, Key Companies, Trends, Growth and Regional Forecasts Research|Coronavirus Impact

Global High Performance Biomaterials Sales Market 2021: Industry Size, Outlook, Share, Demand, Manufacturers and 2026 Forecast Researchs|Coronavirus Impact

https://murphyshockeylaw.net/

Follow this link:
Nanomedicine Market Analysis and Forecast to 2025 by Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview Murphy's...

Recommendation and review posted by Alexandra Lee Anderson

Application of Nanotechnology in the COVID-19 Pandemic | IJN – Dove Medical Press

Dongki Yang

Department of Physiology, College of Medicine, Gachon University, Incheon, 21999, South Korea

Correspondence: Dongki YangDepartment of Physiology, College of Medicine, Gachon University, Incheon 21999, South KoreaTel +82-32-899-6072Fax +82-32-899-6588Email dkyang@gachon.ac.kr

Abstract: COVID-19, caused by SARS-CoV-2 infection, has been prevalent worldwide for almost a year. In early 2000, there was an outbreak of SARS-CoV, and in early 2010, a similar dissemination of infection by MERS-CoV occurred. However, no clear explanation for the spread of SARS-CoV-2 and a massive increase in the number of infections has yet been proposed. The best solution to overcome this pandemic is the development of suitable and effective vaccines and therapeutics. Fortunately, for SARS-CoV-2, the genome sequence and protein structure have been published in a short period, making research and development for prevention and treatment relatively easy. In addition, intranasal drug delivery has proven to be an effective method of administration for treating viral lung diseases. In recent years, nanotechnology-based drug delivery systems have been applied to intranasal drug delivery to overcome various limitations that occur during mucosal administration, and advances have been made to the stage where effective drug delivery is possible. This review describes the accumulated knowledge of the previous SARS-CoV and MERS-CoV infections and aims to help understand the newly emerged SARS-CoV-2 infection. Furthermore, it elucidates the achievements in developing COVID-19 vaccines and therapeutics to date through existing approaches. Finally, the applicable nanotechnology approach is described in detail, and vaccines and therapeutic drugs developed based on nanomedicine, which are currently undergoing clinical trials, have presented the potential to become innovative alternatives for overcoming COVID-19.

Keywords: COVID-19, SARS-CoV-2, antiviral drug, vaccines, nanoparticles, nanotechnology

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Application of Nanotechnology in the COVID-19 Pandemic | IJN - Dove Medical Press

Recommendation and review posted by Alexandra Lee Anderson

Key trends that will shape the future of Nanomedicine Market to 2027 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc The Courier – The…

A Basic Introduction to Nanomedicine Market.

The Nanomedicine market report emphasizes on latest data such as driver, emerging trends, and opportunities. This document also covers other important information such as size, restraints, share, challenges, and major players for the forecast period of 2021-2028. The report includes the SWOT analysis of leader companies from the global Nanomedicine market. It also enlists and analyzes the most recent market developments shaping the future of the foremost players and industry.

The report puts a special emphasis on key driving and restraining factors for the market, along with a comprehensive study of the emerging trends and future developments of the market. The report further provides an elaborate study of micro-and macro-economic aspects that are anticipated to influence the demand for the market.

Inquire for a sample copy of the report @ https://www.stratagemmarketinsights.com/sample/9943

Major players covered in this report: GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A

Following the fundaments, the market is segmented on the basis of geography:

This report studies the top players, focuses on product capacity, production, value, consumption, market share and growth opportunity from this geographies, covering basis of geography: North America (U.S., Canada, Mexico), Europe (U.K., France, Germany, Spain, Italy and Rest of Europe), Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific),Latin America (Brazil, Argentina, Colombia, and Rest of L.A.), Middle East and Africa (Turkey, GCC, UAE and South Africa Rest of Middle East).

Results of the recent scientific undertakings towards the development have been studied. Nevertheless, the factors affecting the leading industry players to adopt synthetic sourcing of the market products have also been studied in this statistical surveying report. As per the report, Nanomedicine market revenue in the year 2020 was USD XX million and is expected to reach USD XX million in the year 2028 at XX% CAGR. It describes current changing market trends to help our clients make astute decisions accordingly. We are also ready to serve with a customized report. According to the need of the clients, this report can be customized and available in a separate report for the specific region.

**NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers to post the COVID-19 crisis.

Report Focus:

Grab Your Report at an Impressive Discount! Please click Here @ https://www.stratagemmarketinsights.com/discount/9943

Secondary Data Sources That We Refer To:

Annual reports, investor presentations, SEC filings, and press releases of companies operating in the market.Website, reports, and press releases of end-user facilities.

Secondary Research Is Conducted To Derive The Following Information:

Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesNumber of procedures and an average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline

COVID-19 Impact on Global Nanomedicine Market

The market report analyses the impact of Coronavirus (COVID-19) on the industry. Since the COVID-19 virus outbreak in December 2020, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency.

Why choose Stratagem Market Insights?

To Access and buy a Complete Report @ https://www.stratagemmarketinsights.com/cart/9943

About Stratagem Market Insights:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with an cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide.

Contact Us:

Stratagem Market Insights

1001 4th Ave,#3200, Seattle, WA 98154, U.S

Delivery Center:

203, 2nd Floor, Bremen Business Center,Aundh, Pune, Maharashtra 411007, India.USA +1-415-871-0703JAPAN +81-50-5539-1737UK +44-203-289-4040Email: sales@stratagemmarketinsights.comExplore By MN

Follow this link:
Key trends that will shape the future of Nanomedicine Market to 2027 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc The Courier - The...

Recommendation and review posted by Alexandra Lee Anderson

Clene Nanomedicine Aims to be the Gold Standard in Neurodegenerative Disease – BioBuzz

Clene Nanomedicine, one of Marylands Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $31.9 million that will be used to advance the companys gold nanocrystal-based treatment for neurodegenerative diseases.

Clene is developing a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals, which are used to amplify bioenergetic reactions in patients in order to drive intracellular biological reactions. Chief Executive Officer Rob Etherington said bioenergetic nanotherapeutics are a clean break from pharmaceutical drug development that uses classical synthetic chemistry.

Using gold as a therapeutic is not a new concept. Gold-salt injections were historically used to treat rheumatoid arthritis decades ago, but were dropped due to health concerns and toxicity issues.

Funds from the merger with Tottenham, a special purpose acquisition company (SPAC), will be used to advance Clenes lead asset, CNM-Au8, a bioenergetic nanocatalyst under development as an add-on treatment for neurodegenerative diseases like Parkinsons disease, multiple sclerosis and Amyotrophic Lateral Sclerosis (ALS). CNM-Au8 is designed to catalyze biocelluar reactions and so far the company has seen the asset live up to its promise in clinical studies.

Although Clenes corporate offices are in Utah, the bulk of the companys research is conducted in Cecil County, Maryland. Approximately three-fourths of the companys employees are located in Maryland, Etherington said. The company conducts all R&D and manufacturing in Maryland, as well as its commercialization activities.

Maryland has been a perfect anchor for Clene, Etherington said.

While the company raised a significant amount of funds through the merger, Etherington said Maryland was one of the companys earliest financial backers through a loan arrangement. He said predicted his company and the state will continue to have a strong relationship in the years ahead.

The state has been a true supporter. It was also gratifying to be recognized as a Future 2020 company because we have built a home in Maryland, he said.

Etherington predicted the next 18 months will be important for the company due to a planned readout of the companys asset. The funds raised in the merger will be used to carry CNM-Au8 into Phase II and Phase III studies that aim to address neurodegenerative diseases of high unmet medical need, such as multiple sclerosis, Parkinsons disease and amyotrophic lateral sclerosis (ALS). CNM-Au8 is currently being assessed in a Phase II study for the treatment of chronic optic neuropathy in patients with multiple sclerosis and is in Phase II and Phase III studies for disease progression in patients with ALS. Both Phase II studies are expected to read out this year. Its also being studied in a Phase II Parkinsons disease trial. The company reported interim data from the study last year and additional data is expected in the first half of 2021. Clene also plans to launch an additional Phase IIb Parkinsons disease efficacy study with CN<-Au8 by the end of the year.

While CNM-Au8 is showing promise, its not designed to replace any medication currently being used by a patient for one of these diseases. Rather, its designed to work alongside those medications. Clenes compound is designed to enhance the intracellular biological actions necessary to repair and reverse neuronal damage, Etherington said.

Clenes gold nanocrystals are grown in treated water and patients drink the product when it is ready. By combining the nanocrystal therapy with ongoing treatments for these neurodegenerative diseases, Etherington said the goal is to reverse neurodegeneration.

We want to let the cell take care of its own housekeeping and enhance whats naturally occurring in the central nervous system, he said.

In addition to the gold nanocrystal compound, Clene is developing a silver and zinc asset for COVID-19. CNM-AgZn17 is Clenes second key asset intended for broad anti-viral and anti-microbial use. A Phase II study is planned in Brazil to treat acutely symptomatic non-hospitalized patients with COVID-19.

Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.

See original here:
Clene Nanomedicine Aims to be the Gold Standard in Neurodegenerative Disease - BioBuzz

Recommendation and review posted by Alexandra Lee Anderson

Global Cancer Nanomedicine Market Booming Demand Leading To Exponential CAGR Growth By 2027 The Courier – The Courier

The Report Titled onCancer Nanomedicine Market Report- Development Trends, Market Size, Industry Opportunities and Competitive Landscape in 2021firstly introduced the Cancer Nanomedicine Industry basics:The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors.The report takes into account theimpact of the COVID-19 pandemic on the Cancer Nanomedicine marketand is perfect for precision and accuracy that will help to meet business requirements at affordable rates. By using Cancer Nanomedicine market report, strengths and weaknesses as well as threats and opportunities for the business can be known. Defining the problem and objectives, collecting and generating market data with the supporting statistics, everything is performed in a streamlined process which makes this report highly accurate.

The information of Cancer Nanomedicine market analysis report covers major technological, scientific and economic developments in industrial, pharmaceutical and high technology organizations. This large scale report helps to achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Market Analysis and Insights: Global Cancer Nanomedicine Market:

Cancer nanomedicine market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 12.50% in the above-mentioned forecast period.

Get more information on Global Cancer Nanomedicine Market Research Report by requesting FREE Sample Copy at:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-nanomedicine-market&AS

The major players who are leading the Cancer Nanomedicine market throughout the globe are:

Market Segmentation

By Type (Inorganic Nanoparticles, Organic Nanoparticles)

By Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents)

Some Of The Major Highlights Of TOC Covers:-

1 INTRODUCTION

1.1 Objectives Of The Study

1.2 Cancer Nanomedicine Market Definition

2 MARKET SEGMENTATION

2.1 Cancer Nanomedicine Markets Covered

2.2 Europe Weight Management Market: Geographical Scope

3 MARKET OVERVIEW

3.1 Drivers

4 EXECUTIVE SUMMARY

4.1 Europe Weight Management Market: Segmentation

5 PREMIUM INSIGHTS

5.1 Increasing Government Initiatives Towards Management And Growing Consumption Of Healthy Diets Are Expected To Drive The Cancer Nanomedicine Market In The Forecast Period Of 2020 To 2027

Continued.

Browse Global Cancer Nanomedicine Market Research Report with detailed TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-nanomedicine-market&AS

Global Cancer Nanomedicine Market Scope and Market Size

Cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for Cancer Nanomedicine market across This section covers regional segmentation which accentuates on current and future demand for COVID-19 Cancer Nanomedicine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions. Further, the report focuses on demand for individual application segment across all the prominent regions.

Get detailed COVID-19 impact analysis on the Cancer Nanomedicine Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-nanomedicine-market&AS

Key Pointers Covered In The Cancer Nanomedicine Market Industry Trends And Forecast To 2027

The study provides an in-depth analysis, current trends, and future estimations of theglobal Cancer Nanomedicine marketto elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the Cancer Nanomedicine market growth is provided.

The Cancer Nanomedicine Industry report provides a qualitative and quantitative analysis of the current External Storage market trends, forecasts, and market size from 2020 to 2027 to determine new opportunities.

Porters Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Extensive analyses of key segments of the industry help understand the types of products and technologies used across various geographical regions.

About Data Bridge Market Research Private Ltd:

Data Bridge Market Research PvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact:

Data Bridge Market Research

US:+1 888 387 2818

UK:+44 208 089 1725

Hong Kong:+852 8192 7475

Email:-Corporatesales@databridgemarketresearch.com

See the rest here:
Global Cancer Nanomedicine Market Booming Demand Leading To Exponential CAGR Growth By 2027 The Courier - The Courier

Recommendation and review posted by Alexandra Lee Anderson

Knee injection shows promise as osteoarthritis treatment in mice – Drug Target Review

Scientists have found that a new knee injection using nanomedicine could prevent the effects of osteoarthritis.

A group of scientists have discovered a potential method to cure osteoarthritis. According to the researchers, a simple knee injection could stop the diseases effects. The study was conducted at the University of Pennsylvania, US.

The researchers showed that they could target a specific protein pathway in mice to halt cartilage degeneration over time. Building on that finding, they were able to show that treating mice with surgery-induced knee cartilage degeneration through the same pathway via nanomedicine could dramatically reduce the cartilage degeneration and knee pain.

Our lab is one of the few in the world studying epidermal growth factor receptor (EGFR) signalling in cartilage and from the beginning, we have found that EGFR deficiency or inactivation accelerates osteoarthritis progression in mice, said one of the researchers Associate Professor Ling Qin. Thus, we proposed that its activation could be used to treat osteoarthritis and in this study, we have proven for the first time that over-activating it inside the knee blocks the progression of osteoarthritis.

The researchers compared typical mice with those that had a ligand that bound to EGFR that was over-overexpressed in chondrocytes, the building blocks of cartilage. This overexpression drives the over-activation of EGFR signalling in knee cartilage. When examining them, the mice with overexpressed HBEGF (the EGFR ligand) were found to consistently have enlarged cartilage, meaning that it was not wearing away like the mice who had normal EGFR activity. Moreover, when these mice aged to adulthood, their cartilage was resistant to degeneration and other hallmarks of osteoarthritis, even if their knees meniscus was damaged.

To further prove that the over-activated EGFR was the reason for the mices resiliency, the researchers found that gefitinib treatments, which are designed to block EFGR function, took away the protection against cartilage degeneration.

In a new series of tests, the researchers created nanotherapeutics by attaching a potent EGFR ligand, transforming growth factor-alpha, onto synthetic nanoparticles, to inject into mice who already had cartilage damage in their knees.

Free EGFR ligands have a short half-life and cannot be retained inside of a joint capsule due to their small size, explained Associate Professor Zhiliang Cheng, the co-corresponding authors on the paper. Nanoparticles help to protect them from degradation, restrict them within the joint, reduce off-target toxicity and carry them deep inside dense cartilage to reach chondrocytes.

When mice were injected with these nanotherapeutics, the researchers saw that they slowed cartilage degeneration and bone hardening, as well as eased knee pain. There also were no major side effects seen in the mice who were treated.

While many of the technical aspects of this application still need to be worked out, the ability to stop or slow the course of osteoarthritis with an injection rather than surgery would dramatically change how we feel and function as we age and after injury, said one of the studys co- authors, Dr Jaimo Ahn.

There is a great unmet medical need for a disease-modifying osteoarthritis drug, Qin said. In the future, we will optimise the drug design and test it in large animals before proceeding to clinical trials. We hope our research could lead to a novel drug that will improve the health and well-being of the more than 27 million osteoarthritis patients in the US.

The findings were published in Science Translational Medicine.

Excerpt from:
Knee injection shows promise as osteoarthritis treatment in mice - Drug Target Review

Recommendation and review posted by Alexandra Lee Anderson

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes – GlobeNewswire

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-

-Publication Further Supports Capricors Exosome Platform Advancement-

LOS ANGELES, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today the publication, in collaboration with researchers at Cedars-Sinai Medical Center, which demonstrates the utility of pathway-enhancing culture conditions and small molecule inhibitors to retain markers of cell therapy potency. The publication titled, Small molecule inhibitors and culture conditions enhance therapeutic cell and EV potency via activation of beta-catenin and suppression of THY1 was published in the international peer-reviewed journal, Nanomedicine: Nanotechnology, Biology and Medicine.

This data from this publication is of significant importance to Capricor because it demonstrates our approach to enhance potency of cells by targeting select signaling pathways. The ability to manipulate cells provides read through to our exosome product candidates which are being engineered to treat specific diseases. We have dedicated the last few years at Capricor to understanding the molecular composition of our exosomes products in order to identify microRNAs of interest for therapeutic development, said Dr. Linda Marbn, Ph.D., CEO of Capricor. This data was the foundation of our new platform, which has allowed us to expand our reach to engineering exosomes that contain RNAs for targeted therapeutic delivery. Further, this elucidation of the mechanisms that are driving potential potency of our cell therapy, CAP-1002 and the exosomes they secrete, correlate to some of the promising clinical data we have seen to date in Duchenne muscular dystrophy.

Key findings include:

Dr. Marbn continued, We know that the exosome is natures delivery system and can serve to carry a variety of biologic signals directly to the cell. Now, we have demonstrated that cells can make exosomes loaded with specific and powerful biologic signals. From these early studies, we have launched our platform which will include vaccines, treatment of monogenic diseases, as well as other targets. We plan to announce further pipeline expansion of our exosome-based product candidates by mid-2021.

The work at Cedars-Sinai Medical Center was supported by NIH R01124074; work by Capricor was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-16-1-0712. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.For more information, visitwww.capricor.comand follow the Company onFacebook,InstagramandTwitter.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on November 13, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricors exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact:Caitlin Kasunich / Raquel ConaKCSA Strategic Communicationsckasunich@kcsa.com/ rcona@kcsa.com212.896.1241 / 212.896.1204

Investor Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com617.435.6602

Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com310.358.3200

Read more from the original source:
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - GlobeNewswire

Recommendation and review posted by Alexandra Lee Anderson

Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis -…

SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, Clene) today announced that its wholly-owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its invention for using its patented clean-surfaced gold nanocrystals for treating patients with multiple sclerosis (MS).

Clene notes that its previously patented gold nanocrystals have surfaces that are substantially free from organic impurities and are therefore clean relative to surfaces of gold nanoparticles made by other processes. The allowed application discloses that these gold nanocrystals can be suspended in water and can be taken orally, for example, by a person with MS.

As the leading developer of clean surfaced nanocrystal therapeutics for humans, we continue to expand our patent estate and are pleased to receive this latest Notice of Allowance from the USPTO. While the only approved treatments for MS today are immunomodulators, we see an opportunity to treat MS through a completely different mechanism of action utilizing the therapeutic bioenergetic effects of catalytic gold nanocrystals, such as CNM-Au8. This Notice of Allowance comes as we are conducting two Phase 2 studies of our lead drug candidate CNM-Au8 in the treatment of MS, stated Rob Etherington, President and CEO of Clene.

MS affects anestimated 1 million people in the U.S. and 2.5 million worldwide, with a treatment market valued at $23 billionglobally.

New data is expected from Clenes REPAIR-MS Phase 2 study of CNM-Au8 in the second half of 2021. Prior interim results from this study showed CNM-Au8 was associated with improvements across key central nervous system (CNS) bioenergetic metabolites.

Clenes VISIONARY-MS Phase 2 study is evaluating the efficacy and safety of CNM-Au8 as a remyelinating and neuro-reparative treatment in stable relapsing MS patients with chronic visual impairment. Interim data from the Phase 2 VISIONARY-MS trial demonstrated notable, exposure-related median improvements in the primary endpoint. Completion of enrollment is expected by the end of 2021.

Clenes worldwide patent portfolio in the new field of clean-surfaced nanocrystal therapeutics includes over 100 patents issued and allowed, with around 30 more pending. The issued patents cover state of matter claims for suspensions and solutions, as well as processes for making the materials, devices for conducting the unique electro-crystal chemistry processes, and methods of using the novel materials, such as in this instance of using clean-surfaced gold nanocrystals for treating patients with MS.

About CNM-Au8

CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, MS and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS, in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.

About Clene

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Clene's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clenes control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clenes ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clenes ability to achieve commercial success for its marketed products and drug candidates, if approved; Clenes ability to obtain and maintain protection of intellectual property for its technology and drugs; Clenes reliance on third parties to conduct drug development, manufacturing and other services; Clenes limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clenes clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled Risk Factors in Clenes recently filed registration statement on Form S-4, as well as discussions of potential risks, uncertainties, and other important factors in Clenes subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactAndrew MielachLifeSci Communications(646) 876-5868amielach@lifescicomms.com

Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com

Source: Clene Inc.

Visit link:
Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis -...

Recommendation and review posted by Alexandra Lee Anderson

Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis – DocWire News

This article was originally published here

Molecules. 2021 Jan 13;26(2):E384. doi: 10.3390/molecules26020384.

ABSTRACT

Patients with advanced prostate cancer can develop painful and debilitating bone metastases. Currently available interventions for prostate cancer bone metastases, including chemotherapy, bisphosphonates, and radiopharmaceuticals, are only palliative. They can relieve pain, reduce complications (e.g., bone fractures), and improve quality of life, but they do not significantly improve survival times. Therefore, additional strategies to enhance the diagnosis and treatment of prostate cancer bone metastases are needed. Nanotechnology is a versatile platform that has been used to increase the specificity and therapeutic efficacy of various treatments for prostate cancer bone metastases. In this review, we summarize preclinical research that utilizes nanotechnology to develop novel diagnostic imaging tools, translational models, and therapies to combat prostate cancer bone metastases.

PMID:33450939 | DOI:10.3390/molecules26020384

Follow this link:
Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis - DocWire News

Recommendation and review posted by Alexandra Lee Anderson

Amyotrophic Lateral Sclerosis Market Anticipates Sizeable Growth at a CAGR of 28% during the forecast period (2020-2030) with the US expected to top…

LAS VEGAS, Jan. 18, 2021 /PRNewswire/ -- The surge in the Amyotrophic Lateral Sclerosis (ALS) market can be attributed to a vast pipeline, initiation of HEALEY ALS platform trials, mutation-specific treatment development in the pipeline, a need for a curative treatment option, increase in the ALS prevalence, effective drug approvals in the past 3-4 years, improvisations in market regulatory guidelines, growing awareness about the disease, along with geographical expansions and meaningful collaborations in the ALS pharma industry.

Amyotrophic Lateral Sclerosis Marketreport offers detailed coverage of the disease, its available treatment options, patient pool, and diagnostic modalities. The report lays down the comprehensive insights into market outlook, upcoming pipeline therapies, and unmet needs along with the major collaboration and funding opportunities in the ALS market landscape.

Some of the highlights of the Amyotrophic Lateral Sclerosis marketreport:

Know more about the report highlights @Amyotrophic Lateral Sclerosis Market Landscape and Forecast

Amyotrophic Lateral Sclerosis, commonly known as Lou Gehrig's disease, is a group of progressive, rare neurological diseases, which are a result of gradual deterioration and death of motor neurons. Over time the muscles weaken, start to twitch (called fasciculations), and waste away (atrophy), eventually, leading the brain to lose its ability to initiate and control voluntary movement.

ALS can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. On the basis of mutation, ALS patients can exhibit mutations such as C9ORF72, SOD1, along with others including TARDBP, FUS, OPTN, ANG, etc., and non-mutated/unidentified mutations. The diagnosed Amyotrophic Lateral Sclerosis prevalent cases in the 7MM are estimated to be 48,112 in 2020, which is further expected to increase by 2030.

The Amyotrophic lateral sclerosis epidemiology section of the report proffers insights into the historical and current Amyotrophic lateral sclerosis (ALS) patient pool and forecasted trends for 7MM. ALS report provides historical as well as forecasted epidemiology segmentation for the study period 2017-30:

Visit, Amyotrophic Lateral Sclerosis Epidemiology, for more information

Amyotrophic Lateral Sclerosis Therapeutic Market Landscape

The Amyotrophic Lateral Sclerosis treatment landscape includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Approved drugs in the ALS market comprises Riluzole, Nuedexta, Radicava, and Tiglutik. Rilutek (Riluzole; Covis Pharmaceuticals) is indicated for the treatment of ALS and the mechanism by which riluzole exerts its therapeutic effects in patients with ALS is still unknown. Another approved drug Tiglutik (riluzole), an oral suspension, is the first and only easy-to-swallow thickened riluzole liquid for ALS and is administered twice daily via an oral syringe. On the other hand, Exservan is an oral Riluzole film used to treat ALS. Nuedexta is available as a combination drug containing dextromethorphan hydrobromide and quinidine sulfate indicated for the treatment of pseudobulbar affect. Radicava (Edaravone; Mitsubishi Tanabe Pharma) is another treatment option for the ALS. During clinical trials, it has shown to decrease the decline of the physical functions, however, it is capable of causing adverse effects owing to its constituent sodium bisulfite.

Request for sample @Amyotrophic Lateral Sclerosis Treatment Marketfor rich insights into treatment modalities

Medications are also be given to manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs also are available to help individuals with pain, depression, sleep disturbances, and constipation. There also exists a variety of tools and mechanical devices such as non-invasive ventilation (NIV) and mechanical ventilation for breathing support to help with ALS such as splints, reach extenders, and grab-bars.

However, the Amyotrophic Lateral Sclerosis therapeutic market lacks a curative approach that can halt or reverse the progression of the disease. Even though Radicava can effectively delay physical disability in ALS patients, however, its high pricing may pose a threat to the overall patient compliance of the drug. Furthermore, the lack of epidemiological data of the disease in the pediatric population hinders the development of novel therapies focused on children below 18 years of age.A poor understanding of the mutations, which form a major cause of the ALS, dims down the ongoing speed of the development of the pipeline therapies. Thus, there is a need for better research opportunities in the domain to facilitate a better understanding of the disease and development of potential novel therapies.

Amyotrophic Lateral Sclerosis Pipeline Therapies

Know more about the top emerging therapies in the ALS market @ Amyotrophic Lateral Sclerosis Drug Pipeline

Amyotrophic Lateral Sclerosis Market Forecast

DelveInsight estimates that approval of novel Amyotrophic Lateral Sclerosis pipeline therapies is expected to give the ALS market size a much-needed boost in the foreseeable future. Although, most of the therapies are going to get commercialized in combination with Riluzole and Radicava. In addition to this, other emerging therapies are under trials while the patient is already following their treatment regimen of Riluzole. Thus, it can be said that the pipeline therapies will be sharing the market share with the available market therapies.

Majority of emerging drugs are focusing on delaying the disease progression, and are not curative. Thus, the ALS market presents immense opportunities for pharmaceutical companies to explore and exploit their ground-breaking therapies and occupy the maximum potential. Here, gene and enzyme replacement therapies, which promise to cure the disease completely, automatically get the upper hand here. Several pharmaceutical companies are investigating novel approaches and joining hands with others to expedite the development of ALS treatment options. Recently, Catalent and BrainStorm entered into an agreement to manufacture NurOwn. Cytokinetics and Astellas entered into the Fast Skeletal Regulatory Activator Agreement, allowing Cytokinetics to exercise exclusive control over the future development and commercialization of reldesemtiv and other FSRA compounds and products. Besides agreements, acquisition spree in the ALS market is quite dominant as well. UCB acquired Ra Pharmaceuticals and got zilucoplan, which is currently in phase III, to its vast portfolio. Similarly, Novus Therapeutics completed the acquisition of Anelixis Therapeutics, which is conducting a phase II clinical trial of AT-1501 for ALS.

Although several clinical trials are ongoing, however, an unsettling thing that might be a snag in the steady growth of the Amyotrophic Lateral Sclerosis market is the quite unpropitious success rate of the clinical trials. The management of ALS is extremely expensive. Expensive drugs like Radicava pose a burden for ALS patients as not everyone can get access to the drug due to its high cost. Thus, the cost-effectiveness of the upcoming therapies is also expected to play a major part in their approval.

Know more about the collaboration and funding ongoing @ Major collaborations in Amyotrophic Lateral Sclerosis Market

Scope of the report

Geography Coverage: The United States, EU5 (Germany, France, Italy, Spain, and the United

Kingdom), Japan.Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).Amyotrophic Lateral Sclerosis Market Segmentation: By Geographies, By Therapies.Key Players Involved: Orphazyme, Biogen/Ionis Pharmaceuticals, MediciNova, AB Sciences, Novus Therapeutics, Seelos Therapeutics, Brainstorm-Cell Therapeutics, Amylyx Pharmaceuticals, Gilead Sciences, PTC Therapeutics, GlaxoSmithKline, Clene Nanomedicine, Alexion Pharmaceuticals, Biohaven Pharmaceuticals, UCB Pharma, and several others.Analysis: Comparative and conjoint analysis of Amyotrophic Lateral Sclerosis Emerging therapies, Attribute AnalysisAmyotrophic Lateral Sclerosis Market trends, pipeline analysis across different stages of development (Phase III and Phase II), and Amyotrophic Lateral Sclerosis Market size by therapies.Tools used: SWOT analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.Case StudiesKOL's ViewsAnalyst's Views

Table of Contents

1

Key Insights

2

Executive Summary of Amyotrophic lateral sclerosis

3

Competitive Intelligence Analysis for Amyotrophic Lateral Sclerosis

4

ALS Market Overview at a Glance

5

ALS - Disease Background and Overview

6

Amyotrophic Lateral Sclerosis Patient Journey

7

Amyotrophic Lateral Sclerosis Epidemiology and Patient Population

8

ALS Treatment Algorithm, Current Treatment, and Medical Practices

9

Amyotrophic Lateral Sclerosis Unmet Needs

10

Key Endpoints of Amyotrophic lateral sclerosis Treatment

11

ALS Marketed Products

12

Amyotrophic Lateral Sclerosis Emerging Therapies

13

ALS Seven Major Market Analysis

14

Attribute analysis

15

Amyotrophic Lateral Sclerosis (7MM) Market Outlook

16

Access and Reimbursement Overview of ALS

17

KOL Views

18

Amyotrophic Lateral Sclerosis Market Drivers

19

ALS Market Barriers

20

Appendix

21

DelveInsight Capabilities

22

Disclaimer

23

About DelveInsight

Related Reports

Amyotrophic Lateral Sclerosis Pipeline Insight

DelveInsight's, "Amyotrophic lateral sclerosis Pipeline Insight, 2020," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Amyotrophic lateral sclerosis pipeline landscape.

Amyotrophic Lateral Sclerosis Epidemiology Forecast

DelveInsight's 'Amyotrophic lateral sclerosis Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Amyotrophic lateral sclerosis (ALS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Multiple System Atrophy Market

DelveInsight's "Multiple System Atrophy (MSA) Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Multiple System Atrophy (MSA), historical and forecasted epidemiology as well as the Multiple System Atrophy (MSA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Multiple Sclerosis Market

DelveInsight's "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Alzheimer's Disease Market

DelveInsight's "Alzheimer's disease Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Alzheimer's disease, historical and forecasted epidemiology as well as the Alzheimer's disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Aneurysmal Subarachnoid Hemorrhage Market

DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Binge Eating Disorders Market

DelveInsight's "Binge (Eating) Disorders - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Binge (Eating) Disorders, historical and forecasted epidemiology as well as the Binge (Eating) Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur[emailprotected]+1(919)321-6187www.delveinsight.com

SOURCE DelveInsight Business Research, LLP

Read this article:
Amyotrophic Lateral Sclerosis Market Anticipates Sizeable Growth at a CAGR of 28% during the forecast period (2020-2030) with the US expected to top...

Recommendation and review posted by Alexandra Lee Anderson


Page 3«..2345..1020..»